Supplementary Information

Mid-infrared spectral classification of endometrial cancer compared to benign controls in serum or plasma samples.

David Mabwa, Ketankumar Gajjar, David Furniss, Roberta Schiemer, Richard Crane, Christopher Fallaize, Pierre L Martin-Hirsch, Francis L Martin, Theordore Kypraios, Angela B Seddon, Sendy Phang

No. of Pages = 11 No. of Figures = 8 No. of Tables = 2



Figure S1. Spectral data collected from endometrial plasma cancer and control patients. Top row shows the spectra before any pre-processing was performed and the bottom row shows the spectra after the following pre-processing steps were performed: 1. Cut spectra (1430 cm⁻¹ – 900 cm⁻¹ – LEFT COLUMN, or 1800 cm⁻¹ – 900 cm⁻¹ – RIGHT COLUMN), SG-filtering (polynomial order of 5) and spectral derivation (1st Order) and vector normalisation. These spectra are only a representation of the full sample, therefore only 80 random individual spectra are shown.



Endometrial Serum

Figure S2. Spectral data collected from endometrial serum cancer and control patients. Top row shows the spectra before any pre-processing was performed and the bottom row shows the spectra after the following pre-processing steps were performed: 1. Cut spectra (1430 cm⁻¹ – 900 cm⁻¹ – LEFT COLUMN, or 1800 cm⁻¹ – 900 cm⁻¹ – RIGHT COLUMN), SG-filtering (polynomial order of 5) and spectral derivation (1st Order) and vector normalisation. These spectra are only a representation of the full sample, therefore only 80 random individual spectra are shown.



Figure S3. Important features found in endometrial plasma and serum in the 1430 cm⁻¹ to 900 cm⁻¹ region. Blue line plot shows the PCA loadings/weightings obtained by performing PCA on derivatised spectra. These loadings, which are validated by a two-sample t-test, indicate the importance of each wavenumber. Orange line plot (P-value) shows the result of the independent samples t-test, indicating the significance of each wavenumber. If the P-value exceeds 0.05 he corresponding wavenumber is deemed insignificant. Significant features are indicated by red arrows.



Figure S4. Important features found in endometrial plasma and serum in the 1800 cm⁻¹ to 900 cm⁻¹ region. Blue line plot shows the PCA loadings/weightings obtained by performing PCA on derivatised spectra. These loadings, which are validated by a two-sample t-test, indicate the importance of each wavenumber. Orange line plot (P-value) shows the result of the independent samples t-test, indicating the significance of each wavenumber. If the P-value exceeds 0.05 the corresponding wavenumber is deemed insignificant. Significant features are indicated by red arrows.

EndoCncr *EndoCtrl*



Figure S5. The PCA outcome from endometrial plasma (1430 cm⁻¹ to 900 cm⁻¹). Nine PCs accounting for 95% variance in the dataset were found. On the x-axis, PC 1 to PC 9 are shown from left to right, while on the y-axis, they are shown from top to bottom. Blue dots refer to cancer (*EndoCncr*). Orange dots refer to control (*EndoCtrl*).

197 The 0.1 - Top to Bottom 28.2 一款 12.30 4.1 -0.05 -0.1 -0.15 0. 0.05 PC 1 to PC 8 -0.05 0.05 Principal Components – -0.05 -0.1 57 0.1 * 1 1 3 0.05 ļ -, ant a 12 144 0.04 0.02 -0.02 -0.1 0.1 -0.1 -0.05 0.05 0.05 -0.1 -0.05 0.05 -0.02 0.02 0 0 0.1 0 0 0.05 0.1 0 Principal Components – PC 1 to PC 8 – Top to Bottom

EndoCncr *EndoCtrl*

Figure S6. The PCA outcome from endometrial plasma (1800 cm⁻¹ to 900 cm⁻¹). Eight PCs accounting for 95% variance in the dataset were found. On the x-axis, PC 1 to PC 8 are shown from left to right, while on the y-axis, they are shown from top to bottom. Blue dots refer to cancer (*EndoCncr*). Orange dots refer to control (*EndoCtrl*).

210,00 The second - Parts The second - 10 - 5 1 - Gall Stor -. . -02 - Top to Bottom -0.4 ------The A.E. 50. -0.1 -0.3 1.000 ... ------T 1º -X and and 4 5 1 1 -0 0.1 0.05 (the state A CO 1 to PC 11 12 0.02 the second -0.02 N. 1.51 Car C 0.1 1. 0.05 ЫС - Jungland Principal Components ---0.05 --0.1 0.02 THE REAL PROPERTY. ant. the Stores 1 Mart in the 1.44 -- States -0.02 -0.04 -0.06 0.05 1 4.8 18 -0.05 0.04 0.02 1 -0.02 -0.1 -0.05 0 -0.4 -0.2 0 -0.2 0 -0.1 0 0.1 0 0.05 0.1 0.02 0 0.05 0.1 -0.04 0.05 0 0.04

EndoCncr *EndoCtrl*

Principal Components – PC 1 to PC 11 – Top to Bottom

Figure S7. The PCA outcome from endometrial serum (1430 cm⁻¹ to 900 cm⁻¹). Eleven PCs accounting for 95% variance in the dataset were found. On the x-axis, PC 1 to PC 11 are shown from left to right, while on the y-axis, they are shown from top to bottom. Blue dots refer to cancer (*EndoCncr*). Orange dots refer to control (*EndoCtrl*).

EndoCncr

EndoCtrl



Principal Components – PC 1 to PC 10 – Top to Bottom

Figure S8. The PCA outcome from endometrial serum (1800 cm⁻¹ to 900 cm⁻¹). Ten PCs accounting for 95% variance in the dataset were found. On the x-axis, PC 1 to PC 11 are shown from left to right, while on the y-axis, they are shown from top to bottom. Blue dots refer to cancer (*EndoCncr*). Orange dots refer to control (*EndoCtrl*).

| Wavenumber / cm ⁻¹ - Plasma | Wavenumber / cm ⁻¹ - Serum | Tentative Assignments | Vibrational Modes |
|---|--|---|--|
| - | 1423 | Fatty acids, amino acid side chains | C=O stretching of -COO |
| - | 1393 | Proteins, lipids | Symmetric C-H deformation of CH_3 |
| 1369 | - | Tyrosine, guanine | Stretching C-N |
| 1358 | 1358 | Fatty acids, amino acid side chains | C=O stretching of -COO ⁻ , CH ₂ wagging for proline |
| 1312, 1288 | 1346, 1308, 1292 | Proteins | C-N/N-H deformation (Amide III) |
| 1246, 1215 | 1254 | Nucleic acids (cfDNA), phospholipids | Asymmetric P=O stretching in PO ₂ |
| 1173 | 1192, 1165 | Polysaccharides, carbohydrates | C-O-C and C-O-P stretching and ring vibrations, Symmetric C-O stretching coupled to C-O-H bending |
| 1092 | 1088 | Nucleic acids (cfDNA), phospholipids | Symmetric stretching in PO ₂ , CO- O-C symmetric stretching vibration |
| 1038 | - | Carbohydrates | Symmetric C-O-C stretching |
| 999 | 999 | Carbohydrates | Symmetric C-O stretching |
| - | 937 | Carbohydrates or fatty acids | C-O or C-C stretching |

Table S1. Important features found in endometrial plasma and serum in the 1430 cm⁻¹ to 900 cm⁻¹ region, with vibrational modes and tentative assignments [1].

| Wavenumber / cm ⁻¹ – Plasma | Wavenumber / cm ⁻¹ - Serum | Tentative Assignments | Vibrational Modes |
|---|--|--|--|
| 1755, 1736 1720 | 1778, 1766, 1720 | Phospholipids, thymine, uracyl | C=O stretching vibration of esters |
| 1670 | 1690, 1670 | Proteins | Anti-parallel β -sheet, turns and loops |
| 1643, 1605 | 1643, 1601 | α-helix, proteins (fibrinogen) | C=O stretch of Amide I group |
| 1570 | 1535, 1508 | Proteins (fibrinogen) | N-H bending, C-H stretching, C-O bending, C-C and N-C stretching (Amide II band) |
| - | 1467, 1450 | Lipids, proteins, nucleic acids | Symmetric and asymmetric C-H scissoring of $-CH_2$ |
| 1423 | 1423 | Fatty acids, amino acid side chains | C=O stretching of -COO |
| 1389 | 1389 | Proteins (fibrinogen), lipids | Symmetric C-H deformation of CH_3 |
| - | 1358 (falling edge of 1400) | Fatty acids, amino acid side chains | C=O stretching of -COO ⁻ , CH ₂ wagging for proline |
| 1346 | 1346, 1308 | Proteins | C-N/N-H deformation (Amide III) |
| 1207 (edges of 1235) | 1254 (edges of 1235) | Nucleic acids (cfDNA), phospholipids | Asymmetric P=O stretching in PO ₂ |
| - | 1161 | Polysaccharides, carbohydrates | C-O-C and C-O-P stretching and ring vibrations, Symmetric C-O stretching coupled to C-O-H bending |
| - | 1099 | Nucleic acids (cfDNA), phospholipids | Symmetric stretching in PO ₂ , CO-O-C symmetric stretching vibration |
| 999 (descending edge of 1030) | 1007 (descending edge of 1030) | Carbohydrates | Symmetric C-O-C/C-O stretching |
| 968 | 937 | Carbohydrates or fatty acids | C-O, C-C stretching |

Table S2. Important features found in endometrial plasma and serum in the 1800 cm⁻¹ to 900 cm⁻¹ region, with vibrational modes and tentative assignments [1, 2].

References

[1] L. Shi and R. R. Alfano, Deep imaging in tissue and biomedical materials: Chapter 8: Biomedical applications in probing deep tissue using mid-infrared supercontinuum optical biopsy, Singapore: Pan Standord Publishing Pte. Ltd., 2017.

[2] M. Boix, S. Eslava, G. C. Machado, E. Gosselin, N. Ni, E. Saiz and J. D. Coninck, "ATR-FTIR measurements of albumin and fibrinogen adsorption: Inert verses calcium phosphate ceramics," *Journal* of Biomedical Materials Research Part A, vol. 103, no. 11, pp. 3493-3502, 2015.